期刊
ACADEMIC EMERGENCY MEDICINE
卷 18, 期 9, 页码 947-958出版社
WILEY
DOI: 10.1111/j.1553-2712.2011.01150.x
关键词
-
资金
- Abbott
- BRAHMS
- Biosite
- Inverness
- Siemens
- Roche
- Nanosphere
- Response Biomedical
- Bayer
Objectives: Few tools exist that provide objective accurate prediction of short-term mortality risk in patients presenting with acute heart failure (AHF). The purpose was to describe the accuracy of several biomarkers for predicting short-term death rates in patients diagnosed with AHF in the emergency department (ED). Methods: The Biomarkers in ACute Heart failure (BACH) trial was a prospective, 15-center, international study of patients presenting to the ED with nontraumatic dyspnea. Clinicians were blinded to all investigational markers, except troponin and natriuretic peptides, which used the local hospital reference range. For this secondary analysis, a core lab was used for all markers except troponin. This study evaluated patients diagnosed with AHF by the on-site emergency physician (EP).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据